The Food Industry’s Panic: How Big Sugar is Lobbying Against the Weight Loss Drug Craze

You can sense it before you can name it if you walk into any large supermarket in the United States today. The long, fluorescent sections of cookies, chips, and sweetened cereals that have dominated American grocery shopping for decades are being subtly rearranged in the center aisles. Where family-size bags used to be, smaller packages are starting to appear. “Simply” and “Better For You” banners on companies whose reputations were based on the exact opposite attributes. cereals with high-protein claim labels that were marketed mainly to kids until recently. The food sector is redecorating. And the reason it’s redecorating is because a tiny injectable drug has subtly destroyed the foundation upon which processed food profits were established.

Ozempic, Wegovy, and their growing class of successors are examples of GLP-1 medications that suppress hunger and lessen what users sometimes refer to as “food noise”—the incessant background mental chatter about eating that many people experience. People eat less when that noise stops. They consume significantly less of the categories that are most important to packaged food companies, but they consume less of everything. Among GLP-1 users, dessert consumption has decreased by 84%. The consumption of alcohol has decreased by 33%. The size of family grocery baskets is decreasing by 4% to 6%. The drop is as high as 9% among households headed by a single person. GLP-1 users cut their calorie intake by 40% on average. According to EY-Parthenon, dietary modifications associated with GLP-1 use may result in a $12 billion decline in snack sales over the following ten years. That isn’t a quarterly earnings rounding error. In an industry that was not designed to handle it, that is a structural change.

For about two years, the industry’s first instinct was to downplay the threat in public. It was deemed exaggerated by executives. Reassuring notes were released by analysts. The sugar industry has been using the same rhetorical strategy for decades to divert attention away from the role that its products play in obesity: consumers are resilient, the problem is complex, and the data is preliminary. The earnings calls then began to shift. In their 2026 earnings calls, nearly three dozen non-healthcare companies discussed GLP-1 medications or weight loss, compared to just five the year before and 14 the year before. There is no longer a wait-and-see attitude. Companies that adopted it are now catching up to those that began adapting sooner.

With the introduction of “Simply NKD,” PepsiCo has reformulated its snacks with shorter ingredient lists and no artificial coloring. With its Sabra and Siete brands, it is experimenting with mini-meal options. Coca-Cola is pushing for quicker innovation and increased the production of Fairlife protein milk. Since launching higher-protein Cheerios in December 2024, General Mills has seen a 23% increase in its capital expenditure forecast for 2026. Nestlé went one step further and developed a product line called “Vital Pursuit” specifically designed for GLP-1 users. This was a noteworthy instance in which a food company formally acknowledged that a drug has altered the needs and identity of its customers. The CEO of Magnum Ice Cream reported that while GLP-1 users still consume sweets, they exhibit “a stark reduction of mindless munching and binge eating.” Delivered calmly at an investor conference, that statement effectively acknowledges that the fundamental driver of junk food profitability—habitual, emotional, and careless eating—is being pharmacologically disrupted on a large scale.

It makes sense that the sugar industry is uncomfortable right now, and this is not wholly unrelated to its past. After all, this is the same industry that supported Harvard nutritionists in the 1970s through the Sugar Research Foundation to conduct studies that blamed fat rather than sugar for obesity. The low-fat craze, a decades-long nutritional deception that pushed Americans toward high-sugar “healthy” products and accelerated the obesity epidemic the medications are currently being used to treat, was sparked by this funding, which was recorded in internal industry records and subsequently examined in scholarly literature. The corn industry was equally opportunistic, spending over $30 million between 2008 and 2014 to change the public’s perception of high-fructose corn syrup. In 2010, it even petitioned the FDA to rename it “corn sugar” in order to disassociate it from its complex associations. The FDA turned it down. The rates of obesity continued to rise.

In February 2026, global sugar prices fell to a five-year low, with traders attributing part of the drop to faster-than-anticipated consumption declines brought on by GLP-1 adoption. There is something poetic about that specific data point. The financial tool that sets the price of the world’s supply of sweeteners is now accounting for the potential that fewer people will desire sugar—not due to a tax, regulation, or public health campaign, but rather because a medication is suppressing the craving.

The food industry’s shift to high-protein, high-fiber, portion-controlled products may actually be successful. Before GLP-1s gained widespread use, the market for nutrient-dense food was already expanding, and the medications may hasten this shift. In the words of Peter Mangan of Portage Point Partners, “There’s not anyone out there that’s not designing, putting R&D dollars against this trend.” The question is whether the $12 billion loss estimate turns out to be conservative or if the reformulation taking place in product development labs will outpace the rate at which the customer base is changing. The idea that human appetite was essentially limitless and completely controllable was the foundation upon which the food industry built its profits. Millions of people with a prescription and a weekly injection schedule are now testing that assumption in real time.